Current perspective of stem cell therapies for cardiac regeneration

Therapy

Volumn 8, Issue 1, 2011, Pages 69-82

  Lee, Yee Ki ^a   Siu, Chung Wah ^a   Zhang, Yang ^a   Tse, Hung Fat ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

acute myocardial infarction; bone marrow derived cells; cardiac progenitor cells; embryonic stem cells; induced pluripotent stem cells; myocardial ischemia; skeletal myoblasts

Indexed keywords

ACUTE HEART INFARCTION; ADIPOSE TISSUE; ANGINA PECTORIS; ANGIOGENESIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CARDIAC REGENERATION; CARDIOMYOPATHY; CELL TRANSDIFFERENTIATION; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; EMBRYONIC STEM CELL; ENDOTHELIAL PROGENITOR CELL; FUNCTIONAL STATUS; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEMATOPOIETIC STEM CELL; HUMAN; ISCHEMIC CARDIOMYOPATHY; MESENCHYMAL STEM CELL; MYOBLAST; NONHUMAN; PLURIPOTENT STEM CELL; REVIEW; STEM CELL TRANSPLANTATION; TISSUE REGENERATION; UMBILICAL CORD BLOOD;

EID: 78650933990     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.10.81     Document Type: Review

References (119)

1. Dean TJ, Creese A, Prentice T: The double burden: emerging epidemics and persistent problems. In: The World Health Report 1999. WHO, Geneva, Switzerland, 13 27 (1999).
2. Velagaleti RS, Pencina MJ, Murabito JM et al. Long term trends in the incidence of heart failure after myocardial infarction. Circulation 118, 2057 2062 (2008).
3. Bergmann O, Bhardwaj RD, Bernard S et al. Evidence for cardiomyocyte renewal in humans. Science 324, 98 102 (2009).
4. Nadal Ginard B, Kajstura J, Leri A, Anversa P: Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ. Res. 92, 139 150 (2003).
5. Gepstein L: Derivation and potential applications of human embryonic stem cells. Circ. Res. 91, 866 876 (2002).
6. Segers VF, Lee RT: Stem cell therapy for cardiac disease. Nature 451, 937 942 (2008).
7. Cheng AS, Yau TM: Paracrine effects of cell transplantation: strategies to augment the efficacy of cell therapies. Semin. Thorac. Cardiovasc. Surg. 20, 94 101 (2008).
8. Tse HF, Thambar S, Kwong YL et al. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT CAD trial). Eur. Heart J. 28, 2998 3005 (2007).
9. Quaini F, Urbanek K, Beltrami AP et al. Chimerism of the transplanted heart. N. Engl. J. Med. 346, 5 15 (2002).
10. Gnecchi M, Zhang Z, Ni A, Dzau VJ: Paracrine mechanisms in adult stem cell signaling and therapy. Circ. Res. 103, 1204 1219 (2008).
11. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC: Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 428, 668 673 (2004).
12. Murry CE, Soonpaa MH, Reinecke H et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428, 664 668 (2004).
13. van der Bogt KE, Sheikh AY, Schrepfer S et al. Comparison of different adult stem cell types for treatment of myocardial ischemia. Circulation 118, S121 S129 (2008).
14. Fedak PW: Paracrine effects of cell transplantation: modifying ventricular remodeling in the failing heart. Semin. Thorac. Cardiovasc. Surg. 20, 87 93 (2008).
15. Yeghiazarians Y, Zhang Y, Prasad M et al. Injection of bone marrow cell extract into infarcted hearts results in functional improvement comparable to intact cell therapy. Mol. Ther. 17(7), 1250 1256 (2009).
16. Pagani FD, DerSimonian H, Zawadzka A et al. Autologous skeletal myoblasts transplanted to ischemia damaged myocardium in humans. Histological analysis of cell survival and differentiation. J. Am. Coll. Cardiol. 41, 879 888 (2003).
17. Chiu RC, Zibaitis A, Kao RL: Cellular cardiomyoplasty: myocardial regeneration with satellite cell implantation. Ann. Thorac. Surg. 60, 12 18 (1995).
18. Jain M, DerSimonian H, Brenner DA et al. Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation 103, 1920 1927 (2001).
19. Murry CE, Wiseman RW, Schwartz SM, Hauschka SD: Skeletal myoblast transplantation for repair of myocardial necrosis. J. Clin. Invest. 98, 2512 2523 (1996).
20. Pouzet B, Vilquin JT, Hagege AA et al. Intramyocardial transplantation of autologous myoblasts: can tissue processing be optimized? Circulation 102, III210 III215 (2000).
21. Rajnoch C, Chachques JC, Berrebi A, Bruneval P, Benoit MO, Carpentier A: Cellular therapy reverses myocardial dysfunction. J. Thorac. Cardiovasc. Surg. 121, 871 878 (2001).
22. Scorsin M, Hagege A, Vilquin JT et al. Comparison of the effects of fetal cardiomyocyte and skeletal myoblast transplantation on postinfarction left ventricular function. J. Thorac. Cardiovasc. Surg. 119, 1169 1175 (2000).
23. Taylor DA, Atkins BZ, Hungspreugs P et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat. Med. 4, 929 933 (1998).
24. Menasche P, Hagege AA, Scorsin M et al. Myoblast transplantation for heart failure. Lancet 357, 279 280 (2001).
25. Dib N, Michler RE, Pagani FD et al. Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four year follow up. Circulation 112, 1748 1755 (2005). (Pubitemid 41368151)
26. Gavira JJ, Herreros J, Perez A et al. Autologous skeletal myoblast transplantation in patients with nonacute myocardial infarction: 1 year follow up. J. Thorac. Cardiovasc. Surg. 131, 799 804 (2006).
27. Menasche P, Hagege AA, Vilquin JT et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J. Am. Coll. Cardiol. 41, 1078 1083 (2003).
28. Siminiak T, Fiszer D, Jerzykowska O, Grygielska B, Kalmucki P, Kurpisz M: Percutaneous autologous myoblast transplantation in the treatment of post infarction myocardial contractility impairment report on two cases. Kardiol. Pol. 59, 492 501 (2003). (Pubitemid 38017162)
29. Siminiak T, Kalawski R, Fiszer D et al. Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: Phase I clinical study with 12 months of follow up. Am. Heart J. 148, 531 537 (2004).
30. Suzuki K, Brand NJ, Allen S et al. Overexpression of connexin 43 in skeletal myoblasts: relevance to cell transplantation to the heart. J. Thorac. Cardiovasc. Surg. 122, 759 766 (2001).
31. Thompson RB, Emani SM, Davis BH et al. Comparison of intracardiac cell transplantation: autologous skeletal myoblasts versus bone marrow cells. Circulation 108(Suppl. 1), II264 II271 (2003).
32. Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium. Nature 410, 701 705 (2001).
33. Nygren JM, Jovinge S, Breitbach M et al. Bone marrow derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat. Med. 10, 494 501 (2004).
34. Tse HF, Yiu KH, Lau CP: Bone marrow stem cell therapy for myocardial angiogenesis. Curr. Vasc. Pharmacol. 5, 103 112 (2007).
35. Shantsila E, Watson T, Tse HF, Lip GY: New insights on endothelial progenitor cell subpopulations and their angiogenic properties. J. Am. Coll. Cardiol. 51, 669 671 (2008).
36. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964 967 (1997).
37. Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM: Origin of endothelial progenitors in human postnatal bone marrow. J. Clin. Invest. 109, 337 346 (2002).
38. Shi Q, Rafii S, Wu MH et al. Evidence for circulating bone marrow derived endothelial cells. Blood 92, 362 367 (1998).
39. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143 147 (1999).
40. Makino S, Fukuda K, Miyoshi S et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J. Clin. Invest. 103, 697 705 (1999).
41. Amado LC, Saliaris AP, Schuleri KH et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc. Natl Acad. Sci. USA 102, 11474 11479 (2005).
42. Pittenger MF, Martin BJ: Mesenchymal stem cells and their potential as cardiac therapeutics. Circ. Res. 95, 9 20 (2004).
43. Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418, 41 49 (2002).
44. Yoon YS, Wecker A, Heyd L et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J. Clin. Invest. 115, 326 338 (2005).
45. Planat Benard V, Menard C, Andre M et al. Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ. Res. 94, 223 229 (2004).
46. Planat Benard V, Silvestre JS, Cousin B et al. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation 109, 656 663 (2004).
47. Miyahara Y, Nagaya N, Kataoka M et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat. Med. 12, 459 465 (2006).
48. Gimble JM, Katz AJ, Bunnell BA: Adipose derived stem cells for regenerative medicine. Circ. Res. 100, 1249 1260 (2007).
49. Das H, Abdulhameed N, Joseph M, Sakthivel R, Mao HQ, Pompili VJ: Ex vivo nanofiber expansion and genetic modification of human cord blood derived progenitor/stem cells enhances vasculogenesis. Cell Transplant. 18, 305 318 (2009).
50. Ma N, Stamm C, Kaminski A et al. Human cord blood cells induce angiogenesis following myocardial infarction in NOD/scid mice. Cardiovasc. Res. 66, 45 54 (2005).
51. Ghodsizad A, Niehaus M, Kogler G et al. Transplanted human cord blood derived unrestricted somatic stem cells improve left ventricular function and prevent left ventricular dilation and scar formation after acute myocardial infarction. Heart 95, 27 35 (2009).
52. Beltrami AP, Barlucchi L, Torella D et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114, 763 776 (2003).
53. Kajstura J, Urbanek K, Rota M et al. Cardiac stem cells and myocardial disease. J. Mol. Cell. Cardiol. 45, 505 513 (2008).
54. Li Z, Lee A, Huang M et al. Imaging survival and function of transplanted cardiac resident stem cells. J. Am. Coll. Cardiol. 53, 1229 1240 (2009).
55. Smith RR, Barile L, Cho HC et al. Regenerative potential of cardiosphere derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 115, 896 908 (2007).
56. Andersen DC, Andersen P, Schneider M, Jensen HB, Sheikh SP: Murine cardiospheres are not a source of stem cells with cardiomyogenic potential. Stem Cells 27, 1571 1581 (2009).
57. Odorico JS, Kaufman DS, Thomson JA: Multilineage differentiation from human embryonic stem cell lines. Stem Cells 19, 193 204 (2001).
58. Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A: Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat. Biotechnol. 18, 399 404 (2000).
59. Kehat I, Kenyagin Karsenti D, Snir M et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J. Clin. Invest. 108, 407 414 (2001).
60. He JQ, Ma Y, Lee Y, Thomson JA, Kamp TJ: Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ. Res. 93, 32 39 (2003).
61. Habib M, Caspi O, Gepstein L: Human embryonic stem cells for cardiomyogenesis. J. Mol. Cell. Cardiol. 45, 462 474 (2008).
62. Macia E, Boyden PA: Stem cell therapy is proarrhythmic. Circulation 119, 1814 1823 (2009).
63. Siu CW, Moore JC, Li RA: Human embryonic stem cell derived cardiomyocytes for heart therapies. Cardiovasc. Hematol. Disord. Drug Targets 7, 145 152 (2007).
64. Shih CC, Forman SJ, Chu P, Slovak M: Human embryonic stem cells are prone to generate primitive, undifferentiated tumors in engrafted human fetal tissues in severe combined immunodeficient mice. Stem Cells Dev. 16, 893 902 (2007).
65. Cao F, van der Bogt KE, Sadrzadeh A et al. Spatial and temporal kinetics of teratoma formation from murine embryonic stem cell transplantation. Stem Cells Dev. 16, 883 891 (2007).
66. Park IH, Zhao R, West JA et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451, 141 146 (2008).
67. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861 872 (2007).
68. Yu J, Vodyanik MA, Smuga Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917 1920 (2007).
69. Mauritz C, Schwanke K, Reppel M et al. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation 118, 507 517 (2008).
70. Okita K, Ichisaka T, Yamanaka S: Generation of germline competent induced pluripotent stem cells. Nature 448, 313 317 (2007).
71. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S: Generation of mouse induced pluripotent stem cells without viral vectors. Science 322, 949 953 (2008).
72. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K: Induced pluripotent stem cells generated without viral integration. Science 322, 945 949 (2008).
73. Yusa K, Rad R, Takeda J, Bradley A: Generation of transgene free induced pluripotent mouse stem cells by the piggyBac transposon. Nat. Methods 6, 363 369 (2009).
74. Woltjen K, Michael IP, Mohseni P et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458, 766 770 (2009).
75. Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K: Virus free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458, 771 775 (2009).
76. Soldner F, Hockemeyer D, Beard C et al. Parkinson's disease patient derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136, 964 977 (2009).
77. Kim D, Kim CH, Moon JI et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 4, 472 476 (2009).
78. Smart N, Riley PR: The stem cell movement. Circ. Res. 102, 1155 1168 (2008).
79. Suuronen EJ, Kuraitis D, Ruel M: Improving cell engraftment with tissue engineering. Semin. Thorac. Cardiovasc. Surg. 20, 110 114 (2008).
80. Abdel Latif A, Bolli R, Tleyjeh IM et al. Adult bone marrow derived cells for cardiac repair: a systematic review and meta analysis. Arch. Intern. Med. 167, 989 997 (2007).
81. Lipinski MJ, Biondi Zoccai GG, Abbate A et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta analysis of controlled clinical trials. J. Am. Coll. Cardiol. 50, 1761 1767 (2007).
82. Burt RK, Loh Y, Pearce W et al. Clinical applications of blood derived and marrow derived stem cells for nonmalignant diseases. JAMA 299, 925 936 (2008).
83. Schachinger V, Erbs S, Elsasser A et al. Intracoronary bone marrow derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 355, 1210 1221 (2006).
84. Tendera M, Wojakowski W: Cell therapy success does not come easy. Eur. Heart J. 30, 640 641 (2009).
85. Reffelmann T, Konemann S, Kloner RA: Promise of blood and bone marrow derived stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy. J. Am. Coll. Cardiol. 53, 305 308 (2009).
86. Losordo DW, Schatz RA, White CJ et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double blind, randomized controlled trial. Circulation 115, 3165 3172 (2007).
87. van Ramshorst J, Bax JJ, Beeres SL et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA 301, 1997 2004 (2009).
88. Menasche P, Alfieri O, Janssens S et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo controlled study of myoblast transplantation. Circulation 117, 1189 1200 (2008).
89. Hagege AA, Marolleau JP, Vilquin JT et al. Skeletal myoblast transplantation in ischemic heart failure: long term follow up of the first Phase I cohort of patients. Circulation 114, I108 I113 (2006).
90. Anversa P, Kajstura J, Leri A: If I can stop one heart from breaking. Circulation 115, 829 832 (2007).
91. Tang YL, Zhao Q, Qin X et al. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann. Thorac. Surg. 80, 229 236; discussion 236 237 (2005).
92. Sorrentino SA, Bahlmann FH, Besler C et al. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with Type 2 diabetes mellitus: restoration by the peroxisome proliferator activated receptor g agonist rosiglitazone. Circulation 116, 163 173 (2007).
93. Kissel CK, Lehmann R, Assmus B et al. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J. Am. Coll. Cardiol. 49, 2341 2349 (2007).
94. Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S: Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur. Heart J. 28, 766 772 (2007).
95. Korf Klingebiel M, Kempf T, Sauer T et al. Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. Eur. Heart J. 29, 2851 2858 (2008).
96. Sasaki K, Heeschen C, Aicher A et al. Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc. Natl Acad. Sci. USA 103, 14537 14541 (2006).
97. Zeng L, Hu Q, Wang X et al. Bioenergetic and functional consequences of bone marrow derived multipotent progenitor cell transplantation in hearts with postinfarction left ventricular remodeling. Circulation 115, 1866 1875 (2007).
98. Elmadbouh I, Haider H, Jiang S, Idris NM, Lu G, Ashraf M: Ex vivo delivered stromal cell derived factor 1a promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium. J. Mol. Cell. Cardiol. 42, 792 803 (2007).
99. Ii M, Nishimura H, Iwakura A et al. Endothelial progenitor cells are rapidly recruited to myocardium and mediate protective effect of ischemic preconditioning via 'imported' nitric oxide synthase activity. Circulation 111, 1114 1120 (2005).
100. Shujia J, Haider HK, Idris NM, Lu G, Ashraf M: Stable therapeutic effects of mesenchymal stem cell based multiple gene delivery for cardiac repair. Cardiovasc. Res. 77, 525 533 (2008).
101. Roell W, Lewalter T, Sasse P et al. Engraftment of connexin 43 expressing cells prevents post infarct arrhythmia. Nature 450, 819 824 (2007).
102. Emanueli C, Lako M, Stojkovic M, Madeddu P: In search of the best candidate for regeneration of ischemic tissues: are embryonic/fetal stem cells more advantageous than adult counterparts? Thromb. Haemost. 94, 738 749 (2005).
103. Klug MG, Soonpaa MH, Koh GY, Field LJ: Genetically selected cardiomyocytes from differentiating embronic stem cells form stable intracardiac grafts. J. Clin. Invest. 98, 216 224 (1996).
104. Min JY, Yang Y, Converso KL et al. Transplantation of embryonic stem cells improves cardiac function in postinfarcted rats. J. Appl. Physiol. 92, 288 296 (2002).
105. Behfar A, Zingman LV, Hodgson DM et al. Stem cell differentiation requires a paracrine pathway in the heart. FASEB J. 16, 1558 1566 (2002).
106. Yang Y, Min JY, Rana JS et al. VEGF enhances functional improvement of postinfarcted hearts by transplantation of ESC differentiated cells. J. Appl. Physiol. 93, 1140 1151 (2002).
107. Min JY, Yang Y, Sullivan MF et al. Long term improvement of cardiac function in rats after infarction by transplantation of embryonic stem cells. J. Thorac. Cardiovasc. Surg. 125, 361 369 (2003).
108. Hodgson DM, Behfar A, Zingman LV et al. Stable benefit of embryonic stem cell therapy in myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 287, H471 H479 (2004).
109. Kehat I, Khimovich L, Caspi O et al. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat. Biotechnol. 22, 1282 1289 (2004). (Pubitemid 39341201)
110. Himes N, Min JY, Lee R et al. In vivo MRI of embryonic stem cells in a mouse model of myocardial infarction. Magn. Reson. Med. 52, 1214 1219 (2004).
111. Kofidis T, de Bruin JL, Hoyt G et al. Injectable bioartificial myocardial tissue for large scale intramural cell transfer and functional recovery of injured heart muscle. J. Thorac. Cardiovasc. Surg. 128, 571 578 (2004).
112. Kofidis T, de Bruin JL, Yamane T et al. Insulin like growth factor promotes engraftment, differentiation, and functional improvement after transfer of embryonic stem cells for myocardial restoration. Stem Cells 22, 1239 1245 (2004).
113. Naito H, Nishizaki K, Yoshikawa M et al. Xenogeneic embryonic stem cell derived cardiomyocyte transplantation. Transplant. Proc. 36, 2507 2508 (2004).
114. Laflamme MA, Gold J, Xu C et al. Formation of human myocardium in the rat heart from human embryonic stem cells. Am. J. Pathol. 167, 663 671 (2005).
115. Ke Q, Yang Y, Rana JS, Chen Y, Morgan JP, Xiao YF: Embryonic stem cells cultured in biodegradable scaffold repair infarcted myocardium in mice. Sheng Li Xue Bao 57, 673 681 (2005).
116. Menard C, Hagege AA, Agbulut O et al. Transplantation of cardiac committed mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study. Lancet 366, 1005 1012 (2005).
117. Swijnenburg RJ, Tanaka M, Vogel H et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 112, I166 I172 (2005).
118. Xue T, Cho HC, Akar FG et al. Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: insights into the development of cell based pacemakers. Circulation 111, 11 20 (2005).
119. Singla DK, Hacker TA, Ma L et al. Transplantation of embryonic stem cells into the infarcted mouse heart: formation of multiple cell types. J. Mol. Cell. Cardiol. 40, 195 200 (2006).